Company intelligence / Profile preview

Bionure

Barcelona, Catalonia, Spainbionure.com ↗

Ownership: Private
Development stage: Other

Overview

Bionure has developed neuroprotective compounds such as BN201, which is currently licensed to Oculis and in Phase II clinical trials for optic neuritis. The company is also pioneering RNA therapeutics targeting genetic components of neurodegenerative diseases like ALS and epilepsy. Their approach combines advanced neuroscience with computational systems biology to predict efficacy and develop new therapies.

Therapeutic areas: Neurology
Modalities: Small moleculesRNA therapeutics
Industry: Biotech

Drug pipeline

1 asset

BN201

Partnerships

Hospital del Mar Research Institute (strategic collaboration on RNA therapies)Oculis SA (licensee of BN201)

Beyond the preview

Go deeper on Bionure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionure.